http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. (Medical Xpress)—An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety of advanced or metastatic forms of the disease. Updated data from this Phase 1 clinical trial are being formally presented at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Yale Cancer Center is one of the lead trial sites. The abstract was made public by ASCO in advance of the meeting. http://medicalxpress.com/news/2013-06-drug-cancer-cells-immune.html Cancer Tue, 04 Jun 2013 08:44:23 EST news289554256 (Medical Xpress)—Researchers at the University of Virginia School of Medicine have developed a promising new antibiotic to treat potentially deadly gastrointestinal infections without harming the beneficial probiotic bacteria that help prevent relapse. http://medicalxpress.com/news/2013-04-antibiotic-potentially-deadly-gut-infections.html Diseases, Conditions, Syndromes Fri, 12 Apr 2013 06:15:35 EST news284966118 Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research (AACR) Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them. http://medicalxpress.com/news/2013-04-drug-equals-death-melanoma-cells.html Cancer Tue, 09 Apr 2013 09:40:48 EST news284719242 Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy. http://medicalxpress.com/news/2013-04-paragazole-excels-preclinical-triple-negative-breast.html Cancer Mon, 08 Apr 2013 09:16:30 EST news284631363 The investigational drug AZD5363, which has shown activity in preclinical studies, was well tolerated in humans, and two patients with advanced solid tumors showed partial response, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-akt-inhibitor-azd5363-tolerated-yielded.html Cancer Mon, 08 Apr 2013 09:10:01 EST news284629293 A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine. http://medicalxpress.com/news/2012-11-ponatinib-resistant-chronic-myeloid-leukemia.html Cancer Wed, 28 Nov 2012 17:00:21 EST news273343855 Hospitalized heart failure patients given an investigational drug had improved symptoms and other clinical benefits including fewer deaths, than those given standard of care plus a placebo, according to late-breaking clinical trial research presented at the American Heart Association's Scientific Sessions 2012. http://medicalxpress.com/news/2012-11-drug-hospitalized-heart-failure-patients.html Cardiology Wed, 07 Nov 2012 09:01:29 EST news271501261 (Medical Xpress)—According to the Centers for Disease Control (CDC), endometriosis, a gynecological disorder in which cells from the uterus lining grow in other areas of the body, is the number one reason for a hysterectomy in women ages 18-35.  Current treatment options for endometriosis are severely limited by side effects of existing medications and surgical options have more risks.  A nationwide clinical trial is testing an investigational drug as a potential new option for patients with moderate to severe pain from this disease.  http://medicalxpress.com/news/2012-10-potential-drug-pain-symptoms-endometriosis.html Obstetrics & gynaecology Tue, 09 Oct 2012 09:30:14 EST news268993806 The University of Colorado Cancer Center, together with other participating academic medical centers, recently opened a phase I human clinical trial of the drug OMP-54F28 in patients with advanced solid tumor cancers. OMP-54F28, a candidate investigational drug discovered by OncoMed Pharmaceuticals, targets cancer stem cells (CSCs), also known as tumor-initiating cells, which many researchers believe are at the root of tumor occurrence and growth. These CSCs are notoriously resistant to existing chemotherapies and so may survive current treatments to repopulate a tumor, leading to relapse and metastasis. http://medicalxpress.com/news/2012-10-cu-cancer-center-phase-clinical.html Cancer Wed, 03 Oct 2012 13:24:26 EST news268489437 A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system. http://medicalxpress.com/news/2012-10-harness-immune-stem-cell-transplant.html Immunology Mon, 01 Oct 2012 16:04:31 EST news268326194 (Medical Xpress)—Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an investigational drug believed to hamper cancer cells. http://medicalxpress.com/news/2012-09-brca1-brca2-mutation-treatment-option.html Cancer Thu, 20 Sep 2012 07:45:20 EST news267345911 Researchers at the University of Toronto and the Hospital for Sick Children (SickKids) are paving the way towards individualized medicine for patients with cystic fibrosis.  http://medicalxpress.com/news/2012-08-sickkids-lung-cells-stem-cell.html Medical research Wed, 29 Aug 2012 11:27:51 EST news265458400 An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the August 16, 2012 issue of the New England Journal of Medicine (NEJM). http://medicalxpress.com/news/2012-08-potential-class-drug-ulcerative-colitis.html Diseases, Conditions, Syndromes Wed, 15 Aug 2012 17:00:16 EST news264262927 A pilot study in adolescents and adults has found that an investigational drug shows promise as the first potential medical treatment for children with the severest type of congenital hyperinsulinism, a rare but potentially devastating disease in which gene mutations cause insulin levels to become dangerously high. http://medicalxpress.com/news/2012-08-peptide-blood-sugar-people-congenital.html Diabetes Wed, 01 Aug 2012 16:40:31 EST news263058025 (HealthDay News) -- Researchers say an investigational drug helped improve memory, language, attention and other mental skills in people with early Alzheimer's disease. http://medicalxpress.com/news/2012-07-alzheimer-drug-early-trial.html Alzheimer's disease & dementia Wed, 18 Jul 2012 17:07:30 EST news261850028 An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs. http://medicalxpress.com/news/2012-06-trial-drug-trojan-horse-pancreatic.html Cancer Thu, 14 Jun 2012 09:00:19 EST news258883210 Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown. http://medicalxpress.com/news/2012-06-diabetes-drug-side-effects.html Medical research Mon, 04 Jun 2012 17:51:39 EST news258051090 A new investigational drug significantly reduced urinary cortisol levels and improved symptoms of Cushing's disease in the largest clinical study of this endocrine disorder ever conducted. Results of the clinical trial conducted at centers on four continents appear in the March 8 New England Journal of Medicine and show that treatment with pasireotide cut cortisol secretion an average of 50 percent and returned some patient's levels to normal. http://medicalxpress.com/news/2012-03-experimental-drug-cortisol-symptoms-cushing.html Medical research Wed, 07 Mar 2012 17:00:04 EST news250359314 The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active when combined with traditional lung cancer treatments and other investigational targeted therapies, according to preclinical study data. http://medicalxpress.com/news/2012-01-ganetespib-kras-mutant-nsclc-monotherapy-combinations.html Cancer Wed, 11 Jan 2012 05:06:54 EST news245480807 Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures. In the past 20 years, numerous treatment regimens have been evaluated for locally-advanced pancreatic cancer with high-dose chemotherapy followed by chemoradiation being the current standard approach. However, the median survival time of these patients remains generally less than 12 months. http://medicalxpress.com/news/2011-12-rtog-phase-trial-therapy-ganitumab.html Cancer Wed, 14 Dec 2011 16:38:00 EST news243103071 An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers. http://medicalxpress.com/news/2011-11-achilles-heel-lethal-prostate-cancer.html Cancer Thu, 17 Nov 2011 03:30:52 EST news240723012 (Medical Xpress) -- A new mouthwash developed by a microbiologist at the UCLA School of Dentistry is highly successful in targeting the harmful Streptococcus mutans bacteria that is the principal cause tooth decay and cavities. http://medicalxpress.com/news/2011-11-mouthwash-cavities.html Health Wed, 16 Nov 2011 10:47:28 EST news240662842 Drug companies sponsoring human trials of possible new medications have ethical responsibilities to study participants and to science to disclose the results of their clinical research -- even when product development is no longer being pursued, says a commentary co-authored by a leading UC Davis drug researcher published online today in Science Translational Medicine. http://medicalxpress.com/news/2011-09-commentary-drug-companies-clinical-trial.html Medications Wed, 28 Sep 2011 14:00:12 EST news236432643 Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9, 2011, in Honolulu. http://medicalxpress.com/news/2011-04-drug-involuntary-movements.html Neuroscience Tue, 12 Apr 2011 14:10:03 EST news221835473